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Cancer tissues contain small populations of highly tumorigenic cells termed cancer 
stem cells (CSCs). Immortalized cell lines containing CSCs are valuable and powerful 
experimental tools for research into the characteristics of these stem cells. We previ-
ously reported that the hepatocellular carcinoma cell line Li- 7 includes abundant 
CD13+CD166− CSCs; however, the number of these cells decreases after long- term 
culture as a result of differentiation to non- CSC populations. To ensure consistent and 
reproducible results in experiments using Li- 7 cells, it is important that the CSC popu-
lation is maintained stably regardless of culture duration and passage. In the present 
study, we found that a commercially available culture medium for maintenance of em-
bryonic stem cells and induced pluripotent stem cells, mTeSR1, effectively prevented 
spontaneous differentiation by CD13+CD166− cells to CD13−CD166+ cells and there-
fore maintained the CSC population in Li- 7 cell cultures. CD13+CD166− CSCs main-
tained using this culture medium retained high tumorigenicity after transplantation 
into mice; they also showed the ability to differentiate in vitro into non- CSC popula-
tions in RPMI- 1640 with 10% FBS medium. We analyzed gene expression profiles of 
CSC and non- CSC populations in Li- 7 cultures using an RNA sequencing method. 
Genes such as FGFR, NOTCH1, and JAG1, that are associated with tumorigenicity and 
stemness, were upregulated in the CSC population. Our results suggest that CSCs can 
be maintained in immortalized cancer cell lines cultured over an extended period using 
a medium developed for culture of embryonic/induced pluripotent stem cells.
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1  | INTRODUC TION
Despite recent advances in cancer therapies, many cancers still 
show a high rate of morbidity due to their rapid progression, 
acquisition of tolerance against chemotherapy or radiotherapy, 
distant metastasis, and recurrence. The development of the 
concept of CSCs over the past 2 decades has helped to explain 
the initiation of cancer and the heterogeneity of cells in cancer 
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tissues.1,2 Cancer stem cells are considered to be derived from 
physiological stem cells and thus have characteristics of self- 
renewal and pluripotency. In general, CSCs are resistant to 
conventional chemotherapy and radiotherapy and cause progres-
sion, metastasis, and recurrence of cancer. To overcome these 
problems, therapies that target CSCs are needed.
Cancer stem cells can be identified by flow cytometric analysis 
using specific markers.3 For example, CD133, CD90, CD13, CD44, 
and EpCAM (also known as CD326) have been reported as cell sur-
face markers for liver CSCs.4-7 Other functional properties of CSCs, 
such as high expression of drug efflux- related proteins,8 high ALDH 
enzymatic activity,9 low levels of intracellular reactive oxygen spe-
cies,6 and spheroid- forming tendency in 3- D culture,10 have also 
been utilized to identify liver CSCs.
We previously reported that the human HCC cell line Li- 7 
includes a small number of CD13+CD166− CSCs.11 A unique 
characteristic of the Li- 7 cell line is the heterogeneity in cell popu-
lations due to the retention of CSCs and differentiated non- CSCs. 
However, we also observed that the Li- 7 cell line loses its tumori-
genicity after long- term culture, presumably due to the dominant 
expansion of non- CSCs that differentiate from CSCs. A similar re-
duction in tumorigenicity of Li- 7 cells was reported by another lab-
oratory.12 In order to carry out efficient and reproducible research 
into the mechanisms of tumorigenicity and to develop therapies 
targeting CSCs, the stable in vitro maintenance of CD13+CD166− 
CSCs in Li- 7 cell cultures is necessary.
It is difficult to maintain CSCs efficiently in vitro because they form 
a very small proportion of cells in primary cancer tissues, are prone to 
differentiation in culture, and require a specific microenvironment for 
stemness. Various attempts at maintaining CSCs in vitro have been 
reported. For example, a cell culture using a serum- free medium suc-
ceeded in generating a highly tumorigenic colon CSC- like cell line from 
primary human colon cancer tissues following serial transplantation 
into immunodeficient mice.13 The retroviral transduction of defined 
factors such as OCT3/4, SOX2, and KLF4 into cancer cells has also been 
reported as another route for inducing a CSC- like cell line.14
The present study was initiated to identify long- term culture 
conditions in which the population of CSCs in the Li- 7 cell line was 
maintained. We found that a commercially available culture me-
dium developed for ES cells and iPS cells can effectively maintain 
CD13+CD166− CSCs in Li- 7 cell cultures.
2  | MATERIAL S AND METHODS
2.1 | Cell culture
The human HCC cell line Li- 7 was provided by the RIKEN 
BioResource Research Center (Tsukuba, Japan) through the National 
Bio- Resource Project of the Japanese Ministry of Education, Culture, 
Sports, Science, and Technology/Japan Agency for Medical Research 
and Development. Li- 7 cells were cultured in RPMI- 1640 (Gibco, 
Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 
10% FBS. To maintain the high tumorigenicity of this cell line, Li- 7 
cells were passaged and cultured overnight in RPMI- 1640 supple-
mented with 10% FBS. Next day, almost all cells were attached to 
the culture dish; they were washed once with PBS and then cultured 
in mTeSR1 medium, which was developed for maintenance of ES/
iPS cells (STEMCELL Technologies, Vancouver, BC, Canada), StemFit 
AK02N (Ajinomoto, Tokyo, Japan), Essential 8 (Gibco, Thermo Fisher 
Scientific), or Stem Partner (Kyokuto Pharmaceutical Industrial Co., 
Tokyo, Japan). Cells were incubated at 37°C with a 5% partial pres-
sure of CO2 in a humidified atmosphere. Cells were passaged twice 
per week, usually at approximately 80% confluency. Many repetitions 
(more than 5 times) were carried out for the experiment in which the 
medium was changed from RPMI- 1640 + 10% FBS to mTeSR1.
2.2 | Flow cytometric analysis and cell sorting
The following Abs were used in this study: allophycocyanin- 
conjugated anti- human CD13 (eBioscience, Thermo Fisher Scientific); 
PE- conjugated anti- human CD166, PE- cyanine- 7- conjugated anti- 
human EpCAM and HLA- ABC (BD Biosciences, Franklin Lakes, 
NJ, USA); and PE- Vio770- conjugated anti- human CD166 and 
allophycocyanin- conjugated anti- human CD133/2 (Miltenyi Biotec, 
Bergisch Gladbach, Germany). The cells were harvested with trypsin 
and EDTA and then stained with fluorescent dye- conjugated Abs in 
staining medium (PBS supplemented with 5% FBS) at 4°C for 20 min-
utes. The cells were washed once with staining medium and resus-
pended in staining medium with 7- AAD (BD Biosciences) to exclude 
dead cells. Aggregated cells were excluded from analyses using an 
FSC- W/FSC- H plot. Isotype controls were used to determine nega-
tive cell populations. In relation to cell sorting, analyses after sorting 
were performed to confirm that the purity of sorted cells was more 
than 95%. FACSVerse and FACSAria SORP (both BD Biosciences) 
were used for analysis and cell sorting, respectively.
2.3 | ALDEFLUOR assay
We used an ALDEFLUOR kit (STEMCELL Technologies) to detect 
intracellular ALDH enzymatic activity. The assay was carried out ac-
cording to the manufacturer's instructions. The activated reagent 
is converted by intracellular ALDH into the fluorescent product 
BODIPY- aminoacetate, which is detectable by flow cytometric analy-
sis. As a negative control, cells were treated with 15 μmol/L diethyl-
aminobenzaldehyde. Cells were incubated for 20 minutes at 37°C in 
the presence of the above reagents and were stained with fluorescent 
dye- conjugated Abs and 7- AAD in the ALDEFLUOR buffer (STEMCELL 
Technologies). FACSAria SORP (BD Biosciences) was used for analysis.
2.4 | Spheroid formation assay
Cells sorted by flow cytometry were seeded at 4 × 103 cells per well 
in a 96- well NanoCulture plate- MS (ORGANOGENIX, Kawasaki, 
Japan) with 100 μL NanoCulture medium- R type supplemented with 
10% FBS- R (ORGANOGENIX). Half of the medium was replaced 
with fresh medium twice per week. The number of spheroids with a 
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diameter greater than 100 μm was counted on day 14 using a micro-
scope equipped with a digital camera DP25 (Olympus, Tokyo, Japan).
2.5 | Animal experiments
Four- week- old female BALB/c nu/nu mice were purchased from CLEA 
Japan (Tokyo, Japan). A 200- μL suspension of cells in RPMI- 1640 was 
injected s.c. The mice were killed when apparent s.c. tumors were 
observed. All animal experiments were approved by the Institutional 
Animal Care and Use Committee of RIKEN Tsukuba Branch.
2.6 | Histological and flow cytometric analyses of 
tumors formed in mice
For histological analysis, extracted tumors were fixed in 4% para-
formaldehyde and then paraffin embedded. Sections (3 μm) were cut 
and stained using H&E and analyzed under a microscope equipped 
with a DP25 digital camera (Olympus).
For the flow cytometric analysis, a tumor tissue sample ap-
proximately 8 mm square was cut into a minced state and then 
suspended in RPMI- 1640 supplemented with 1 mg/mL collagenase 
type I (Fujifilm Wako, Osaka, Japan); the suspension was incubated 
for 30 minutes at 37°C. The suspension was filtered through a 40- 
μm cell strainer (BD Biosciences), and the cells were then stained 
with the Abs described above. Mouse cells were excluded from the 
analysis as they were human HLA- ABC- negative. FACSVerse (BD 
Biosciences) was used for analysis.
2.7 | RNA sequencing
Total RNAs were extracted from cells sorted by flow cytometry. RNA 
sequencing was carried out by Hokkaido System Science (Sapporo, 
Japan) using an Illumina HiSeq 2500 platform (Illumina, San Diego, 
CA, USA) with a 100- bp read length. Image output data from the 
sequencer were transformed into raw sequence data by base call-
ing and stored in FastQ format. Data were mapped to the human 
genome using TopHat (http://ccb.jhu.edu/software/tophat/index.
shtml) and quantified using Cufflinks (http://cole-trapnell-lab.github.
io/cufflinks/).
2.8 | Statistics
The data were first analyzed for homogeneity using an F test; subse-
quently, Welch's t tests were used to identify statistically significant 
differences. A value of P < 0.05 was considered significant.
3  | RESULTS
3.1 | Identification of a culture medium for 
maintaining the CSC population of Li- 7 cells
The HCC cell line Li- 7 from the RIKEN Cell Bank (Japan) con-
tained a population of approximately 40% of CD13+CD166− CSCs 
at the beginning of the culture (Figure 1A).11 This population al-
most disappeared after continuous culture in RPMI- 1640 + 10% 
FBS (hereafter RPMI + FBS) for 1 month through several passages 
(Figure 1A,B).
In order to maintain the CD13+CD166− CSC population, we 
tested commercially available media that have been developed for 
human ES cells and iPS cells.15-18 These media consist of basal me-
dium and additional factors, such as basic FGF, insulin, and transfer-
rin, and also contain other factors that are essential for cell survival 
and proliferation under serum- free conditions. Our analyses indi-
cated that some of these media could effectively increase the ex-
pression of CD13 (Figure 1C). We selected the mTeSR1 medium for 
further experiments as the constituent ingredients of this medium 
have been fully disclosed. Moreover, the improvement in cell viabil-
ity was greater after replacing RPMI + FBS with mTeSR1 than with 
other media. After 4 days of culture in mTeSR1, a high proportion 
of CD13+CD166− cells was observed and this did not change even 
after continuous culture for more than 1 month (Figure 1D,E). The 
majority of cells cultured with RPMI + FBS were spindle- shaped 
fibroblast- like cells, whereas those cultured with mTeSR1 were 
round (Figure 1F).
3.2 | Characterization of CD13+CD166− CSCs 
cultured in mTeSR1
We analyzed expression of the CSC markers EpCAM and CD133 
that have been reported in HCC. CD13+ cells expressing EpCAM 
and CD133 increased after culture in mTeSR1 (Figure 2A), and the 
majority of cells expressing both EpCAM and CD133 were present 
in CD13+CD166− cell populations (Figure 2B). In addition, the stem 
cell surface markers SSEA- 4, TRA- 1- 60, and TRA- 1- 81 showed high 
expression in CD13+CD166− cells cultured in mTeSR1 (Figure 2C).
Next, ALDH enzymatic activity was assessed using the 
ALDEFLUOR assay together with flow cytometric analysis using 
CD13 and CD166. CD13+CD166− cells cultured in mTeSR1 showed 
the highest ALDH activity (Figure 2D). An analysis of spheroid 
formation ability, an indicator of tumorigenicity, showed that 
CD13+CD166− cells formed more spheroids than other cell fractions 
(Figure 2E).
We then investigated the differentiation of CD13+CD166− cells 
cultured in mTeSR1 using CD13+CD166− cells sorted by flow cy-
tometry. The cells retained the same phenotype for 2 months 
(Figure 2F). These CD13+CD166− cells were then cultured in 
RPMI + FBS. As expected, the numbers of CD13− cells and CD166+ 
cells gradually increased and CD13+ CD166− cells markedly de-
creased after 84 days of culture in RPMI + FBS (Figure 2F). This 
result indicates that CD13+CD166− cells cultured for an extended 
period in mTeSR1 still possessed the potential to differentiate into 
mature cells (non- CSC).
The in vivo tumorigenicity of cultured cells was examined by 
transplantation into immunodeficient mice. For Li- 7 cells cultured 
in RPMI + FBS, transplantation of ≥2 × 106 cells resulted in tumor 
formation after 8 weeks (Table 1). In contrast, transplantation of 
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2 × 105 Li- 7 cells cultured in mTeSR1 resulted in tumor formation as 
early as 2 weeks. Analysis of transplantation of 4 cell populations 
sorted by flow cytometry (1 × 106 cells of each fraction), CD166− 
or CD166+ cells cultured in RPMI + FBS (Figure 1A, day 46), and 
CD13+CD166− or CD166+ cells cultured in mTeSR1 (Figure 1D, day 
46), showed that only the CD13+CD166− cell population cultured in 
mTeSR1 could form s.c. tumors (Table 1).
3.3 | Histological and flow cytometric analyses of 
tumors derived from cells cultured in mTeSR1
Li- 7 cells (5 × 106) cultured in RPMI + FBS or mTeSR1 (Figure 1A, day 
46 and Figure 1D, day 46, respectively) were transplanted s.c. into 
immunodeficient mice. Tumor tissues formed in the mice after trans-
plantation were harvested, fixed in formalin, paraffin- embedded, 
F IGURE  1 Characteristics of Li- 7 cells cultured in RPMI- 1640 or mTeSR1. A, Flow cytometric analysis of CD13 and CD166 cells in 
cultures using RPMI- 1640 + 10% FBS. Li- 7 cells were obtained from a cell repository and are shown as day 0. B, The percentages of 
CD13+CD166−, CD13+CD166+, CD13−CD166−, and CD13−CD166+ cells in cultures using RPMI- 1640 + 10% FBS at every passage. Results 
shown are representative of 3 independent experiments. C, Flow cytometric analysis of cells cultured in RPMI- 1640 + 10% FBS or 4 other 
media for embryonic stem cells/induced pluripotent stem cells (mTeSR1, StemFit AK02N, Essential 8, and StemPartner). Cells were cultured 
for 15 d and then subjected to analysis. D, Flow cytometric analysis of CD13 and CD166 cells in cultures using in mTeSR1, on days 4 and 46. 
E, The percentages of CD13+CD166−, CD13+CD166+, CD13−CD166−, and CD13−CD166+ cells in cultures using mTeSR1 at every passage. 
Results shown are representative of 3 independent experiments. F, Morphologies of cells in cultures using RPMI- 1640 + 10% FBS or 
mTeSR1. Magnification, ×100
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and thin sections were stained with H&E (Figure 3A). The tumors 
derived from cells cultured in either RPMI + FBS or mTeSR1 were 
similar and consisted of a mixture of tissue with a solid and pseudog-
landular appearance.
Tumor cells derived from cells cultured in mTeSR1 were then 
cultured in RPMI + FBS (Figure 3B). The number of CD166+ cells 
gradually increased, as found for the culture shown in Figure 2F, 
indicating that the tumor cells formed in mice had the potential 
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to differentiate to mature cells (non- CSC) in the in vitro culture 
system.
3.4 | RNA sequence analysis
To identify the genes associated with the tumorigenicity of 
Li- 7 cells, we undertook RNA sequence analyses in 4 cell frac-
tions: CD13+CD166− cells cultured in mTeSR1 for 9 weeks; and 
CD13+CD166−, CD13−CD166−, and CD13−CD166+ cells cultured 
in RPMI + FBS for 3 weeks. Figure 4A,B shows the number of 
upregulated and downregulated genes in the CD13+CD166− cell 
fraction cultured in mTeSR1 compared to the other 3 fractions 
(CD13+CD166−, CD13−CD166−, and CD13−CD166+ cells cultured 
in RPMI + FBS). CD13+CD166− cells cultured in mTeSR1 had 24 
upregulated genes and 25 downregulated genes compared to the 
other fractions. Among these genes, we focused on FGFRs because 
this signaling pathway is known to be important for maintenance 
of ES/iPS cells. FGFR2, FGFR3, and FGFR4 and their downstream 
genes (EGR1, FOS, FOSB, JUN, and ETV4) were upregulated in 
the CD13+ fraction; these genes showed smaller changes in ex-
pression in the CD13− fraction (Figure 4C). In addition, NOTCH1, 
JAG1, and BMP2, which are related to normal stem cell signaling, 
were also upregulated in CD13+CD166− cells cultured in mTeSR1 
(Figure 4D).
4  | DISCUSSION
The decrease in the numbers of CSCs during in vitro culture is a 
problem for research utilizing the Li- 7 cell line. In the present study, 
we found that commercially available serum- free media devised to 
maintain ES/iPS cells were able to maintain CD13+CD166− CSCs in 
the Li- 7 cell line. As the constituent ingredients of mTeSR1 have been 
disclosed and because cell viability was greater in mTeSR1 than in 
other media, we selected it for analyses of the maintenance of CSCs 
in Li- 7. CD13+CD166− cells cultured in mTeSR1 showed a similar level 
of tumorigenicity after transplantation into mice as cells cultured in 
RPMI + FBS; they also showed similar ALDH activity, spheroid for-
mation, and differentiation into CD13−CD166+ cells. In addition, 
xenografted tumors from both cell cultures induced tumors with 
similar histopathological appearances. These results indicated that 
culture in mTeSR1 medium did not alter the major phenotypes of the 
original CSCs of the Li- 7 cell line. To the best of our knowledge, this is 
the first report to show that switching from a serum- based medium 
to a serum- free medium for the culture of ES/iPS cells can efficiently 
maintain CSCs in a cancer cell line.
How does mTeSR1 maintain CSCs? Of note, the addition of 1% 
FBS to mTeSR1 resulted in the failure to maintain CSCs, suggesting 
that FBS includes factor(s) that promote differentiation to non- CSCs 
(Figure S1). However, the absence of FBS in cultures using RPMI did 
F IGURE  2 Characterization of CD13+CD166− cells cultured in mTeSR1. A,B, Flow cytometric analysis of cells cultured in 
RPMI- 1640 + 10% FBS (Li- 7 RPMI) or mTeSR1 (Li- 7 mTeSR1) for 6 wk; the cells were stained using CD13, CD166, epithelial cell adhesion 
molecule (EpCAM), and CD133. B, Population analysis of cells cultured in mTeSR1. CD13+CD166− cells are shown as dark blue dots and 
CD13+CD166+ cells are shown as red dots. C, Flow cytometric analysis with SSEA- 4, TRA- 1- 60, and TRA- 1- 81. The percentages of SSEA- 
4- , TRA- 1- 60- , and TRA- 1- 81- positive cells in CD13+CD166− cells cultured in mTeSR1 or RPMI- 1640 + 10% FBS for 15 wk are shown. D, 
Flow cytometric analysis of intracellular aldehyde dehydrogenase enzymatic activity of CD13+CD166−, CD13+CD166+, and CD13−CD166+ 
cell fractions in cultures using mTeSR1. Results shown are representative of 2 independent experiments. E, Spheroid formation assay. 
CD13+CD166−, CD13+CD166+, and CD13−CD166+ cell fractions were sorted in cultures using mTeSR1. Magnification, ×40. Values are 
mean ± SD of 3 wells. Results shown are representative of 2 independent experiments. F, Phenotypic changes in Li- 7 cells after transfer to 
RPMI- 1640 + 10% FBS. CD13+CD166− cells were sorted from cultures using mTeSR1. Cells cultured in mTeSR1 2 months after sorting (left, 
mTeSR1) and cells transfer to RPMI- 1640 + 10% FBS (right, RPMI) for 84 d are shown. *P <0.05. BAA- , BODIPY- aminoacetate; SSC, side 
scatter
Culture condition Injected cells (Number) 2w 4w 6w 8w 12w
RPMI- 1640 + 10% FBS Bulk (1 × 106) 0/4 0/4 0/4 0/4 –
(2 × 106) 0/4 0/4 0/4 1/4 –
(5 × 106) 0/4 0/4 0/4 1/4 −
CD166− (1 × 106) 0/2 0/2 0/2 0/2 0/2
CD166+ (1 × 106) 0/2 0/2 0/2 0/2 0/2
mTeSR1 Bulk (2 × 105) 2/4 4/4 − − −
(5 × 105) 4/4 − − − −
CD13+CD166− (1 × 106) 0/2 1/2 2/2 − −
CD166+ (1 × 106) 0/1 0/1 0/1 0/1 0/1
Bulk Li- 7 cells and cells sorted by flow cytometry from cultures using RPMI- 1640 + 10% FBS or 
mTeSR1 were transplanted s.c. Tumor formation was assessed at 2, 4, 6, 8, and 12 weeks after trans-
plantation. Results are presented as the number of mice with tumors/total number of transplanted 
mice. -, sacrificed.
TABLE  1 Tumor formation assay in 
immunodeficient mice
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not significantly improve the maintenance of CSCs (Figure S2). Taken 
together, removal of FBS from the culture medium (serum- free con-
dition) appears to be a pivotal factor but to be insufficient for main-
tenance of CSCs.
The fact that the optimal conditions for maintaining CSCs were 
at least partly similar to those for ES/iPS cells raises the question 
of whether the gene phenotypes of Li- 7 CSCs are similar to those 
of ES/iPS cells. The CSC population of Li- 7 cells cultured in mTeSR1 
showed high expression of pluripotent stem cell markers such as 
SSEA- 4, TRA- 1- 60, and TRA- 1- 8119,20 and of the signaling genes 
found in normal stem cells such as NOTCH1, JAG1, and BMP2.21-
23 In addition, genes related to the FGF signaling pathway were 
upregulated in the CSC population cultured in mTeSR1. It is well 
known that the FGF signaling pathway is essential for maintaining 
human ES/iPS cells, and the culture media for ES/iPS cells (includ-
ing mTeSR1) contain basic FGF.24 The FGF signaling pathway might 
F IGURE  3 Characterization of tumors 
formed in immunodeficient mice. A, 
The histology of tumors formed in mice 
after transplantation of cells cultured 
in RPMI- 1640 + 10% FBS (RPMI) or 
mTeSR1. Tumor sections were stained 
with H&E. Magnification, ×200. B, Flow 
cytometric analysis using CD13 and 
CD166. Tumor cells derived from cells 
cultured in mTeSR1 were then cultured 
in RPMI- 1640 + 10% FBS for 35 d. 
Results shown are representative of 3 
independent experiments
F IGURE  4 RNA sequence analysis. 
A,B, The number of genes upregulated (A) 
and downregulated (B) in CD13+CD166− 
cells cultured in mTeSR1 compared 
to CD13+CD166−, CD13−CD166−, 
or CD13−CD166+ cells cultured in 
RPMI- 1640 + 10% FBS. C, Expression 
levels of genes encoding fibroblast 
growth factor receptors (FGFRs) and 
their downstream transcriptional factors. 
Expression levels are compared with 
the CD13−CD166+ cells showing the 
lowest tumorigenicity of cells cultured 
in RPMI- 1640 + 10% FBS. Results from 
ANPEP(CD13) and ALCAM(CD166) are 
also shown as positive and negative 
controls, respectively. D, Results of RNA 
sequence analysis for NOTCH1, JAG1, and 
BMP2. Expression levels are compared 
with CD13−CD166+ cells showing 
lowest tumorigenicity of cells cultured in 
RPMI- 1640 + 10% FBS. FC, fold change
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be important for the maintenance of CSCs. However, the addition 
of basic FGF to cell cultures using RPMI did not significantly in-
crease the numbers of CD13+ cells (Figure S2), strongly indicating 
that other factors must be involved. The mechanism for mainte-
nance of ES/iPS cells might have aspects in common, at least in 
part, with that for CSCs. Based on these results, we speculate that 
use of culture media designed for ES/iPS cells could be a desirable 
approach to maintaining CSCs, not only for HCC but also for other 
types of cancer cells.
Li- 7 is a valuable HCC cell line as it contains a CSC population 
that can be exploited for a range of experimental investigations. 
We previously reported that culture of Li- 7 cells in conventional 
culture medium (RPMI + FBS) resulted in the loss of the CSC 
population accompanied by changes in cell phenotypes and loss 
of tumorigenicity.11 These results were confirmed here. Human 
cancer cell lines containing CSCs are very rare, and it is unclear 
how Li- 7 was generated as a cell line containing CSCs. The Li- 7 
cell line was initially maintained as a tumor tissue by serial trans-
plantation into immunodeficient mice, and finally derived as an in 
vitro cultured cell line from tumor cells formed in a mouse.25 We 
speculate that CSCs might have been retained during the mainte-
nance as a tumor tissue; the derived in vitro cultured cell line was 
deposited in a cell repository after short- term culture. If depo-
sition had occurred after long- term culture, it is likely that the 
CSC population of Li- 7 would have disappeared. Although there 
are many types of human cancer cell lines in cell repositories 
around the world, the majority of these lines were subjected to 
long- term culture in vitro before deposition. If CSCs are prone to 
differentiate into mature cells (non- CSCs) in conventional serum- 
based culture media, it is likely that cancer cell lines containing 
CSCs will be very rare.
In future work, we shall continue to explore different culture 
conditions to identify the optimal method for maintenance of CSCs 
and shall also analyze the functions of genes identified here in the 
RNA sequence analysis in order to determine the mechanisms of tu-
morigenicity and to identify an effective regulatory strategy against 
CSCs.
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